Next 10 |
home / stock / eyen / eyen articles
Eyenovia, Inc. (NASDAQ: EYEN) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially...
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite falling around 0.1% on Thursday. The Dow traded up 0.01% to 39,912.06...
Shares of Fluent Inc (NASDAQ:FLNT) fell sharply during Thursday's session after posting weaker-than-expected quarterly results. Fluent posted ...
The Dow Jones index closed higher by over 400 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern ...
NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a commercial-stage ophthalmic pharmaceutical technology company, toda...
Shares of SOPHiA GENETICS SA (NASDAQ: SOPH) fell sharply during Tuesday’s session after the company reported worse than expected fourth-quar...
Taiwan-based Formosa Pharmaceuticals and AimMax Therapeutics announced Monday that the FDA approved clobetasol propionate ophth...
The Dow Jones closed lower by around 80 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around t...
William Blair initiated coverage on Eyenovia Inc (NASDAQ: EYEN), a biopharma company focused on developing therapies based on its Op...
News, Short Squeeze, Breakout and More Instantly...
Eyenovia Inc. Company Name:
EYEN Stock Symbol:
NASDAQ Market:
Eyenovia, Inc. (NASDAQ: EYEN) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially...
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite falling around 0.1% on Thursday. The Dow traded up 0.01% to 39,912.06...